National Learning & Action Network Series: February 2019

Topic: Patient-Centered Treatment Options for Type 2 Diabetes

Date: Wednesday, February 132019


This event was open to beneficiaries, families, healthcare providers, practitioners, partners, End Stage Renal Disease Networks, and Quality Innovation Network-Quality Improvement Organizations.

Event Description:

Selecting the right treatment options for type 2 diabetes has never been more promising, or as complicated as it is today. With all of the current classes of diabetes medications, how does a clinician-patient team decide on the most appropriate medications along the course of a person’s disease process, many of whom also have cardiovascular disease, heart failure, or chronic kidney disease? Join us to learn the latest type 2 diabetes consensus recommendations and decision-trees to help seniors and their care teams decide how to maximize care quality while mitigating risk and treatment burden. This call will feature an author of Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Click here for the flyer for this event.

Learning Objectives:

After participating in the event, learner will be able to:

  • Discuss factors affecting treatment selection for type 2 diabetes
  • Use or recommend SGLT2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes, atherosclerotic cardiovascular disease, heart failure and chronic kidney disease
  • Appropriately use or recommend GLP-1 receptor agonists as the first injectable for type 2 diabetes treatment, ahead of insulin

Slides & Recorded Presentation:

Meet the Speakers:

John Buse, MD, PhD
University of North Carolina School of Medicine

Diana Isaacs, PharmD, BCPS, BC-ADM, CDE
Cleveland Clinic Diabetes Center

Patrick Gee, PhD, JLC
Beneficiary/​Healthcare Consultant/​Patient Advocate

Supplemental Resources: